Blood test may predict ICU death risk for cancer patients

NCT ID NCT07656311

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed in the ICU for more than 24 hours between 2020 and 2025. No new tests or treatments are given—the goal is simply to see if MPV levels are linked to survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could give doctors a simple, early way to identify which cancer patients in the ICU are at highest risk, helping them make faster treatment decisions.
What could go wrong: This is an observational study that only looks back at past records. It cannot prove cause and effect, and the results may not apply to all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Critical Illness neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CRITICAL ILLNESS MORTALITY

Contacts and locations

Locations

Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital

Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.